MorphoSys Reports Prelim 2023 and Q4 Monjuvi US Net Product Sales of $92.0M and $24.1M, Expects 2024 US Net Product Sales of $80M-$95M
Portfolio Pulse from Benzinga Newsdesk
MorphoSys AG (NASDAQ:MOR) reported preliminary 2023 Monjuvi U.S. net product sales of $92.0M and Q4 sales of $24.1M. The company expects 2024 sales to be between $80M-$95M, consistent with its original 2023 guidance. Growth is anticipated from new indications being studied in Phase 3 trials. The 2023 gross margin for Monjuvi is 69%, affected by one-time inventory write-offs. Full financial results will be released on March 13, 2024.
January 30, 2024 | 8:23 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MorphoSys AG reported strong preliminary sales for Monjuvi in 2023 and provided a stable outlook for 2024, with potential growth from new indications in ongoing trials.
The reported preliminary sales figures for Monjuvi are positive, indicating strong performance in 2023. The stable sales outlook for 2024, along with potential growth from new indications, is likely to be viewed positively by investors. The high relevance score is due to the direct mention of MorphoSys and its product Monjuvi. The importance is high as sales figures and forecasts are critical for investors. The confidence level is high due to the specificity of the reported figures and clear guidance provided.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100